Basilea Pharmaceutica AG (BSLN.SW)
| Previous close | 40.25 |
| Open | 40.60 |
| Bid | 0.00 x 0 |
| Ask | 40.35 x 0 |
| Day's range | 40.25 - 40.65 |
| 52-week range | 32.00 - 49.00 |
| Volume | |
| Avg. volume | 36,715 |
| Market cap | 483.729M |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 46.86 |
| EPS (TTM) | 0.86 |
| Earnings date | 13 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 11 Apr 2013 |
| 1y target est | 66.75 |
Globe NewswireBasilea shareholders approve all proposals of the board of directors at the annual general meeting
Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the f
- Globe Newswire
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial p
GlobeNewswireBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the US Food and Drug Administration (FDA) approved ZEVTERA® (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), i
